DuoPlavin (clopidogrel;acetylsalicylic acid)
- Region
- 🇪🇺 EU
- Active substance
- clopidogrel;acetylsalicylic acid
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Status
- Application withdrawn
- Therapeutic area
- Vascular Surgical Procedures; Peripheral Vascular Diseases; Myocardial Infarction; Acute Coronary Syndrome
- Application
- EMEA/H/C/000874
- Official record
- www.ema.europa.eu
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 DuoPlavin Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan) Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) Authorised · Sanofi-Aventis Groupe
- 🇪🇺 Clopidogrel/Acetylsalicylic acid Teva Withdrawn · Teva Pharma B.V.
- 🇪🇺 DuoCover Application withdrawn · Bristol Myers Squibb Pharma EEIG
Follow DuoPlavin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.